Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia

NCT ID: NCT01502163

Last Updated: 2012-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although several measures for prevention of perioperative hypothermia have been introduced the last decades, perioperative hypothermia is still a frequent complication and associated with a negative outcome.

For not long lasting surgery without specific risk for hypothermia the standard procedure for prevention of perioperative hypothermia is insulation. However, the insulation is often not effective enough to prevent intra- and postoperative hypothermia. The implementation of a prewarming is difficult because of variable OR schedules and therefore not often applied.

In the planed prospective, multicenter, randomised-controlled trial will the efficacy of a convective prewarming system on prevention of intra- and perioperative hypothermia (Thermoflect™, TSCI, Amersfoort, NL) be compared to an intraoperative application of forced air warming with or without passive insulation before induction of anesthesia.

The studied prewarming device is easy to use and will be applied on the nursery ward 30-60 minutes before transfer of the patient to the OR.

Perioperative hypothermia is a common complication in general aesthesia. Perioperative hypothermia is associated with medical risks as intraoperative impaired coagulation due to reversible platelet dysfunction, a prolonged bleeding time and increased intraoperative blood loss. In the postoperative course the perioperative hypothermia is especially for patients with cardiopulmonary diseases a relevant problem. Not at least sensual cold and shivering is uncomfortable for the patient.

The study is conducted as a multicenter, prospective, randomised controlled trial. All patients will receive intraoperatively a forced air warming device (Termoflect™/Mistral Air ™). For one intervention group will additionally the insulation with the Thermoflect™ will be applied on nursery ward, the second intervention group will receive additionally a convective air warmer/ reflective blanket (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL) preoperatively on study day on nursery ward.

The aim of the study is to prove the hypothesis that a preoperative insulation with a commercial insulation material (Thermoflect™, TSCI, Amersfoort, NL) leads to a lower incidence of perioperative hypothermia in general anesthesia. The second hypothesis is, that an active prewarming (Thermoflect™ with Mistral Air™, TSCI, Amersfoort, NL) is associated with a more less incidence of periopative hypothermia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Perioperative Hypothermia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

* No prewarming
* Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)
* Passive insulation with Thermoflect™ material.
* All fluids administrated intraoperative will be warmed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Group passive prewarming

* Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)
* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
* All fluids administrated intraoperative will be warmed.

Group Type ACTIVE_COMPARATOR

Thermoflect [TM] passive insulation

Intervention Type DEVICE

passive insulation in the preoperative phase, befor induction of anesthesia

Group Active prewarming

* Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)
* Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.
* All fluids administrated intraoperative will be warmed.

Group Type ACTIVE_COMPARATOR

Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)

Intervention Type DEVICE

Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thermoflect [TM] passive insulation

passive insulation in the preoperative phase, befor induction of anesthesia

Intervention Type DEVICE

Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)

Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 75 years
* BMI from 20 to 30 kg/m2
* Risk class ASA I to III
* Scheduled time for surgery 30 to 120 minutes
* Scheduled anaesthesia with remifentanil, propofol, rocuronium and sevofluran
* Ability of informed consent

Exclusion Criteria

* Adipositas permagna
* Risk class ASA IV to V
* Hypo- and Hyperthyroidism
* Febrile infection
* Pregnancy
* Scheduled time for surgery \< 30 or \> 120 minutes
* Known incompatibility for midazolam, remifentanil, propofol oder rocuronium
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UZ Gent, Belgium

UNKNOWN

Sponsor Role collaborator

Policlinica de Guipuzcoa, San Sebastian, Spain

UNKNOWN

Sponsor Role collaborator

University of Göttingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. T. Perl

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michel Quintel, Prof

Role: STUDY_CHAIR

University Göttingen, Germany

Thorsten Perl, MD

Role: PRINCIPAL_INVESTIGATOR

University Göttingen, Germany

Koen Reyntjens, MD

Role: PRINCIPAL_INVESTIGATOR

UZ Gent, Belgium

Juan Zamballos, Prof.

Role: PRINCIPAL_INVESTIGATOR

Policlinica de Guipuzcoa, San Sebastian, Spain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Gent

Ghent, , Belgium

Site Status

Department of Anesthesiology, Emergency- and Intensive Care Medicine

Göttingen, , Germany

Site Status

Policlinica de Guipuzcoa

Donostia / San Sebastian, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11/4/11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.